PE20231047A1 - Inhibidores de interleucina-17 - Google Patents
Inhibidores de interleucina-17Info
- Publication number
- PE20231047A1 PE20231047A1 PE2023001510A PE2023001510A PE20231047A1 PE 20231047 A1 PE20231047 A1 PE 20231047A1 PE 2023001510 A PE2023001510 A PE 2023001510A PE 2023001510 A PE2023001510 A PE 2023001510A PE 20231047 A1 PE20231047 A1 PE 20231047A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- substituted
- carboxamido
- acetamido
- pyrazole
- Prior art date
Links
- 102000013691 Interleukin-17 Human genes 0.000 title abstract 3
- 108050003558 Interleukin-17 Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical group [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 abstract 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical group CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 1
- JFMPKWXGPUYIMX-QHCPKHFHSA-N CC(C(C(C=CC(NC([C@H](C1CCCCC1)NC(C1=CC=NN1C)=O)=O)=C1)=C1F)=C(C=C1)Cl)=[N+]1[O-] Chemical compound CC(C(C(C=CC(NC([C@H](C1CCCCC1)NC(C1=CC=NN1C)=O)=O)=C1)=C1F)=C(C=C1)Cl)=[N+]1[O-] JFMPKWXGPUYIMX-QHCPKHFHSA-N 0.000 abstract 1
- FWQDZOAPGRWDIL-LSYYVWMOSA-N CC(C=C[N+]([O-])=C1C)=C1C(C=C1)=CC=C1NC([C@H]([C@@H]1C2=CC=CC=C2CCC1)NC(C1=CC=NN1C)=O)=O Chemical compound CC(C=C[N+]([O-])=C1C)=C1C(C=C1)=CC=C1NC([C@H]([C@@H]1C2=CC=CC=C2CCC1)NC(C1=CC=NN1C)=O)=O FWQDZOAPGRWDIL-LSYYVWMOSA-N 0.000 abstract 1
- -1 N-pyridyl Chemical group 0.000 abstract 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 abstract 1
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000003566 oxetanyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invencion se refiere a compuestos de 2-formamido (N-fenil y N-piridil) acetamida sustituidos con N-oxidos de piridina que son inhibidores de interleucina-17 (IL-17) de formula (I), donde R1 es (a) o (b); R6 es H, F, Cl, alquilo C1-C3 o fluoroalquilo C1-C3; R7 es H, F, Cl, alquilo C1-C3 o fluoroalquilo C1-C3; R8 es H, halo, alquilo C1-C3 o hidroximetilo; X es C o N y cuando X es N, R3 esta ausente; R2 se selecciona entre H y F; R3 es H, F o Cl; R4 es H o F; R5 es un heteroarilo de 5 miembros que comprende 1 o 2 heteroatomos seleccionados entre N, S, y O, y en donde dicho heteroarilo es insustituido o sustituido con uno o dos grupos seleccionados entre alquilo C1-C3 y cicloalquilo C3-C4, en donde dicho alquilo C1-C3 es insustituido o sustituido con uno o mas grupos seleccionados entre F, OH, alcoxi C1-C3, -C(O)OH y NR1bR1c, en donde R1b y R1c son H o alquilo C1-C3; o R5 es un heteroarilo de 5 miembros que comprende un atomo de N en donde dicho heteroarilo de 5 miembros se fusiona a un heterociclo de 6 miembros que comprende un atomo de N en donde dicho heterociclo es insustituido o sustituido con un grupo seleccionado entre alquilo C1-C3, alcoxi C1-C3 alquilo C1-C3, -C(O)alquilo C1-C3, cicloalquilo C3-C4 y oxetanilo; Z es -CHR)-; R9 es cicloalquilo C5-C8 monociclico, bicicloalquilo C6, entre otros. Son compuestos preferidos: 2,4-dimetil-3-(4-((S)-2-(1-metil-1H-pirazol-5-carboxamido)-2-((S)-1,2,3,4-tetrahidronaftalen-1-il)acetamido)fenil)piridina 1-oxido; 4-cloro-3-(4-((S)-2-ciclohexil-2-(1-metil-1H-pirazol-5-carboxamido)acetamido)-2-fluorofenil)-2-metilpiridina 1-oxido; 2,4-dimetil-3-(4-((S)-2-(1-metil-1H-pirazol-5-carboxamido)-2-((1r,4S)-4-metilciclohexil)acetamido)fenil)piridina 1-oxido; entre otros.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20205121 | 2020-11-02 | ||
| PCT/IB2021/060092 WO2022091056A1 (en) | 2020-11-02 | 2021-11-01 | Interleukin-17 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231047A1 true PE20231047A1 (es) | 2023-07-11 |
Family
ID=73059405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001510A PE20231047A1 (es) | 2020-11-02 | 2021-11-01 | Inhibidores de interleucina-17 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230391782A1 (es) |
| EP (1) | EP4237417A1 (es) |
| JP (1) | JP2023547470A (es) |
| KR (1) | KR20230091945A (es) |
| CN (1) | CN116323596A (es) |
| AR (1) | AR123962A1 (es) |
| AU (1) | AU2021368247B2 (es) |
| CA (1) | CA3190738A1 (es) |
| CL (1) | CL2023001220A1 (es) |
| CO (1) | CO2023005280A2 (es) |
| CR (1) | CR20230180A (es) |
| DO (1) | DOP2023000081A (es) |
| EC (1) | ECSP23030375A (es) |
| IL (1) | IL302447A (es) |
| MX (1) | MX2023005076A (es) |
| PE (1) | PE20231047A1 (es) |
| TW (1) | TW202227408A (es) |
| UY (1) | UY39484A (es) |
| WO (1) | WO2022091056A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023025783A1 (en) | 2021-08-23 | 2023-03-02 | Leo Pharma A/S | Small molecule modulators of il-17 |
| WO2023111181A1 (en) | 2021-12-16 | 2023-06-22 | Leo Pharma A/S | Small molecule modulators of il-17 |
| WO2023166172A1 (en) | 2022-03-04 | 2023-09-07 | Leo Pharma A/S | Small molecule modulators of il-17 |
| WO2024115662A1 (en) | 2022-12-02 | 2024-06-06 | Leo Pharma A/S | Small molecule modulators of il-17 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6562333B1 (en) | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
| US20050070567A1 (en) | 2002-08-12 | 2005-03-31 | The Regents Of The University Of Michigan | Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| ES2533074T3 (es) | 2010-04-26 | 2015-04-07 | Novartis Ag | Medio de cultivo celular mejorado |
| EP2809660B1 (en) | 2012-02-02 | 2016-01-20 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| JP6196678B2 (ja) | 2012-10-24 | 2017-09-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| WO2014066726A2 (en) | 2012-10-26 | 2014-05-01 | Ensemble Therapeutics Corporation | Compounds for modulating il-17 |
| UY35315A (es) | 2013-02-08 | 2014-09-30 | Novartis Ag | Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios |
| SG10202100916PA (en) | 2015-02-02 | 2021-02-25 | Valo Early Discovery Inc | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
| CA3121719A1 (en) | 2018-12-19 | 2020-06-25 | Leo Pharma A/S | Amino-acid anilides as small molecule modulators of il-17 |
-
2021
- 2021-10-25 UY UY0001039484A patent/UY39484A/es unknown
- 2021-10-29 AR ARP210103016A patent/AR123962A1/es unknown
- 2021-11-01 EP EP21801650.9A patent/EP4237417A1/en active Pending
- 2021-11-01 WO PCT/IB2021/060092 patent/WO2022091056A1/en active Application Filing
- 2021-11-01 PE PE2023001510A patent/PE20231047A1/es unknown
- 2021-11-01 MX MX2023005076A patent/MX2023005076A/es unknown
- 2021-11-01 CN CN202180067298.6A patent/CN116323596A/zh active Pending
- 2021-11-01 IL IL302447A patent/IL302447A/en unknown
- 2021-11-01 TW TW110140649A patent/TW202227408A/zh unknown
- 2021-11-01 CA CA3190738A patent/CA3190738A1/en active Pending
- 2021-11-01 JP JP2023526268A patent/JP2023547470A/ja active Pending
- 2021-11-01 CR CR20230180A patent/CR20230180A/es unknown
- 2021-11-01 US US18/033,100 patent/US20230391782A1/en active Pending
- 2021-11-01 KR KR1020237016828A patent/KR20230091945A/ko active Search and Examination
- 2021-11-01 AU AU2021368247A patent/AU2021368247B2/en active Active
-
2023
- 2023-04-26 DO DO2023000081A patent/DOP2023000081A/es unknown
- 2023-04-26 CO CONC2023/0005280A patent/CO2023005280A2/es unknown
- 2023-04-26 EC ECSENADI202330375A patent/ECSP23030375A/es unknown
- 2023-04-27 CL CL2023001220A patent/CL2023001220A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023547470A (ja) | 2023-11-10 |
| CN116323596A (zh) | 2023-06-23 |
| DOP2023000081A (es) | 2023-06-15 |
| AU2021368247A1 (en) | 2023-05-18 |
| IL302447A (en) | 2023-06-01 |
| US20230391782A1 (en) | 2023-12-07 |
| AU2021368247A9 (en) | 2023-10-05 |
| UY39484A (es) | 2022-06-30 |
| EP4237417A1 (en) | 2023-09-06 |
| AR123962A1 (es) | 2023-01-25 |
| AU2021368247B2 (en) | 2023-10-05 |
| KR20230091945A (ko) | 2023-06-23 |
| WO2022091056A1 (en) | 2022-05-05 |
| CR20230180A (es) | 2023-05-25 |
| MX2023005076A (es) | 2023-05-16 |
| CA3190738A1 (en) | 2022-05-05 |
| CO2023005280A2 (es) | 2023-05-19 |
| ECSP23030375A (es) | 2023-05-31 |
| CL2023001220A1 (es) | 2023-12-22 |
| TW202227408A (zh) | 2022-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231047A1 (es) | Inhibidores de interleucina-17 | |
| PE20191757A1 (es) | Compuestos heterociclicos utiles como inhibidores dobles de atx/ca | |
| PE20220141A1 (es) | Inhibidores de la proteina tirosina fosfatasa | |
| PE20150339A1 (es) | Carboxamidas heterociclicas fungicidas | |
| AR075209A1 (es) | Derivados de 4-amino-5-oxo-7,8-dihidropirimido (5,4-f) (1,4) oxazepin-6 (5h)-il) fenilo | |
| AR045218A1 (es) | Aminas ciclicas inhibidoras de bace-1 que poseen una benzamida sustituyente; composiciones farmaceuticas que las contienen y su uso en la fabricacion de medicamentos para tratar enfermedades cognitivas o neurodegenerativas. | |
| AR045219A1 (es) | Aminas ciclicas inhibidoras de base - 1 que poseen un sustiuyente heterociclico | |
| SE7714607L (sv) | 1,4-dihydropyridin-derivat, substituerade i 2-stellning, forfarande for framstellning derav samt anvendning derav som lekemedel | |
| PT1289955E (pt) | Piperidinas para utilizacao como antagonistas dos receptores da orexina | |
| ATE487715T1 (de) | Triazolderivate als modulatoren von dopamin-d3- rezeptoren | |
| DK1414302T3 (da) | 7-aminotriazolopyrimidiner til bekæmpelse af skadelige svampe | |
| AR055563A1 (es) | Compuestos de piridil acido acetico, agente farmaceutico y utilizacion del compuesto para preparar dicho agente | |
| RU2007146513A (ru) | Фунгицидные производные 2-пиридилметиленкарбоксамида | |
| AR111466A1 (es) | Inhibidores de hdac6 selectivos | |
| RU2010154400A (ru) | Гетероциклическое соединение | |
| RU2017145924A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORy) | |
| AR112795A1 (es) | Compuestos heterocíclicos fungicidas de tiazol | |
| AR070263A1 (es) | Derivados de oxazepinopirimidinona arilamido sustituidos, utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, medicamentos que los contienen y proceso de preparacion e intermediarios. | |
| AR073609A1 (es) | COMPUESTOS DE ANILLO FUSIONADO Y USO DE LOS MISMOS EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVACIoN DE LA GLUCOQUINASA. | |
| MD3759083T2 (ro) | Derivați de 2,4-diaminochinazolină și utilizarea acestora în tratarea infecțiilor virale, a cancerului sau a alergiilor | |
| AR113842A1 (es) | Derivados de tiazol microbiocidas | |
| CA2797767A1 (en) | Bicyclic compound derivatives and their use as acc inhibitors | |
| ATE151757T1 (de) | Heterozyklisch verbindungen mit schädlingsbekämpfungswirkung | |
| PE20181002A1 (es) | Derivados del acido 5-(n- bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
| PE20221025A1 (es) | Inhibidores de los receptores a2c adrenergicos |